Osteomalacia - 32 Studies Found
Recruiting |
: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia :
: 2012-01-29 : Drug: 68Ga-DOTATATE Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. T |
Recruiting |
: Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia : Tumor Induced Oncogenic Osteomalacia : 2015-01-05 |
Active, not recruiting |
: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome : Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome : 2016-03-07 : Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range |
Active, not recruiting |
: Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS) :
|
Recruiting |
: Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia : Hypophosphatemia : 2012-08-05 |
Completed |
: Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia :
: 2004-12-17 |
Terminated |
: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) : Osteomalacia : 2012-12-11 : Drug: Osteomalacia |
Recruiting |
: 68Ga-DOTATATE PET/CT in Oncogenic Osteomalacia :
: 2012-01-29 : Drug: 68Ga-DOTATATE Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. T |
Completed |
: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia : X-linked Hypophosphatemic Rickets/Osteomalacia : 2014-07-02 : Drug: KRN23 Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg |
Active, not recruiting |
: A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome : Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome : 2016-03-07 : Drug: KRN23 Doses may be titrated to achieve the target peak serum phosphorus range |